Acarix receives order from the first freestanding Emergency Room in the US
Kurs
+8,70%
Likviditet
0,92 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-13 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Extra Bolagsstämma 2024 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-28 | - | Extra Bolagsstämma 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Extra Bolagsstämma 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-08-11 | - | Extra Bolagsstämma 2020 |
| 2020-05-15 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-16 | - | Extra Bolagsstämma 2019 |
| 2019-05-17 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2018-05-23 | - | Årsstämma |
| 2018-05-23 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-26 | - | Bokslutskommuniké 2017 |
| 2017-11-14 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the CADScor System has been added to the diagnostic tools available at Tucson ER & Hospital. Tucson ER & Hospital offers advanced emergency and hospital care to the Tucson, Arizona, community through a team of experienced emergency room physicians, skilled ER nurses, and medical technicians.
Tucson ER & Hospital is a part of Nutex Health (NASDAQ: NUTX), bringing communities accessible, concierge-level care they can trust. Nutex Health is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops, and operates innovative healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 20 facilities in 8 States.
“We are thrilled to announce the integration of the CADScor System within a state-of-the-art facility like Tucson ER & Hospital,” commented Acarix President & CEO Aamir Mahmood. “Speed and accuracy are two of the most important considerations when it comes to patient care in the Emergency Department, and we are proud to offer the CADScor System as a tool to help physicians quickly make informed clinical decisions for their patients at point of care."
For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com
About Acarix
| Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com |